Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group (Q73039402)
Jump to navigation
Jump to search
scientific article published on 01 February 1997
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group |
scientific article published on 01 February 1997 |
Statements
Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group (English)
A M Fein
G R Bernard
G J Criner
E C Fletcher
J T Good
W A Knaus
H Levy
G M Matuschak
H M Shanies
R W Taylor
1 February 1997